CURRICULUM VITAE

1. Personal Details

Family name, first name: Purim Ofer

Date & place of birth: February 10, 1970, Address (Office): Department of Oncology, Assuta Academic Hospital, 7747629, Israel (Residence): 6 Wengrover Street, Petach Tikva, Israel Telephone number (Office): +972-72-3398127 (Residence): +972-77-2002848 Cellular phone number: +972-52-4841199 Fax number: +972-72-3399087 E-mail address: [email protected]

2. Academic Education

1992-1995 Sackler Faculty of Medicine, University, Tel Aviv, Israel Subject: Life Sciences BSc degree

1996-1998 School of Dentistry, Tel Aviv University, Tel Aviv, Israel

1998-2002 University of Szeged, Szeged, Hungary Subject: Medicine

MD degree [Cum Laude] Title of Doctoral Dissertation: Identification of sentinel node with gamma probe with technetium in melanoma patients

3. Professional Training

2003 Internship, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel

2004-2010 Resident in Institute of Oncology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel

2008 GCP course, Shefayim, Israel

3. Professional Training

2010-2017 Attending Physician, Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel

Since 11/17 Head of Gastrointestinal Malignancy Service, Assuta Academic Hospital, Ashdod, Israel

4. Board Certification

Passed Oncology Step A 2007 Passed Oncology Step B 2009 Oncology Specialty 2009

5. Professional Licensing

Medical License #37134 2002 Specialty License #28470 2009

6. Employment History

Year Position Department Institution 2003 Internship Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel 2004-2010 Resident Institute of Oncology Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel 2010-2017 Attending Institute of Oncology Rabin Medical Center – Physician Beilinson Hospital, Petach Tikva, Israel Since Nov 2017 Head Gastrointestinal Assuta Academic Hospital, Malignancy Service Ashdod, Israel

7. Academic Appointments

Year Title (Rank) Department Faculty University 2006 Tutor Oncology Sackler Tel Aviv University

9. Membership in Professional/Scientific Societies

Year Name of Society 2004 Israel Medical Association 2005 Israel Society of Clinical Oncology and Radiotherapy 2010 American Society of Clinical Oncology

11. Additional Functions (Committee memberships, academic and administrative functions)

Year Function Since 2008 Gave Frontal Lectures to Family Physicians, Nurses, Oncological Residents, Pharmacists

13. Scientific Publications Hindex h-index 6 Sum of Times Cited 252 Without self citations 247

Refereed articles in scientific journals

1. Articles Published

1. Kundel Y*, Purim O*, Figer A, Stemmer SM, Tichler T, Sulkes J, Sulkes A, Brenner B. (*Equal Contribution) Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer. Med Sci Monit. 2008 Apr;14(4):CR190-5. (MEDICINE, RESEARCH & EXPERIMENTAL JR 89/128, Q3, IF 1.585, CI 1)

2. Joachims Z, Feinmesser R, Purim O, Halpern M, Brenner B, Fenig E, Roizman P, Sulkes J, Feinmesser M. Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma. Appl Immunohistochem Mol Morphol. 2008 Oct;16(5):442-6. (ANATOMY & MORPHOLOGY JR 8/21, Q2, IF 1.634, CI 4)

3. Kundel Y, Brenner R, Purim O, Peled N, Idelevich E, Fenig E, Sulkes A, Brenner B. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option? Dis Colon Rectum. 2010 Dec;53(12):1624-31. (SURGERY JR 32/197, Q1, IF 3.519, CI 43)

4. Brenner B*, Hoshen MB*, Purim O*, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. (*Equal Contribution) MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011 Sep 21;17(35):3976-85. (GASTROENTEROLOGY & HEPATOLOGY JR 30/79, Q2, IF 3.365, CI 76)

5. Kundel Y*, Purim O*, Idelevich E, Lavrenkov K, Man S, Kovel S, Karminsky N, Pfeffer RM, Nisenbaum B, Fenig E, Sulkes A, Brenner B. (*Equal Contribution) Postoperative chemoradiation for resected gastric cancer--is the Macdonald Regimen Tolerable? A retrospective multi-institutional study. Radiat Oncol. 2011 Sep 29;6:127. (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING JR 38/127, Q2, IF 2.568, CI 9)

6. Dreznik A, Purim O, Idelevich E, Kundel Y, Sulkes J, Sulkes A, Brenner B. Gastric cancer: biology and clinical manifestations in Israel. J Surg Oncol. 2012 Mar;105(3):316-22. (SURGERY JR 43/197, Q1, IF 2.993, CI 3) 1. Articles Published

7. Ben Aharon I*, Purim O*, Kundel Y, Brenner R, Gordon N, Sulkes A, Brenner B. (*Equal Contribution) The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience. Anticancer Drugs. 2012 Mar;23(3):313-20. (PHARMACOLOGY & PHARMACY JR 135/257, Q3, IF 2.320, CI 5)

8. Rath-Wolfson L, Purim O, Ram E, Morgenstern S, Koren R, Brenner B. Expression of estrogen receptor β1 in colorectal cancer: correlation with clinicopathological variables. Oncol Rep. 2012 Jun;27(6):2017-22. (ONCOLOGY JR 125/217, Q3, IF 2.662, CI 5)

9. Weissmann-Brenner A, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, Kundel Y, Morgenstern S, Halperin M, Niv Y, Brenner B. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int J Oncol. 2012 Jun;40(6):2097-103. (ONCOLOGY JR 105/217, Q2, IF 3.079, CI 39)

10. Goldberg N*, Kundel Y*, Purim O*, Bernstine H, Gordon N, Morgenstern S, Idelevich E, Wasserberg N, Sulkes A, Groshar D, Brenner B. (*Equal Contribution) Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol. 2012 Aug 1;7:124. (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING JR 38/127, Q2, IF 2.568, CI 19)

11. Purim O, Gordon N, Brenner B. Cancer of the colon and rectum: potential effects of sex-age interactions on incidence and outcome. Med Sci Monit. 2013 Mar 20;19:203-9. (MEDICINE, RESEARCH & EXPERIMENTAL JR 89/128, Q3, IF 1.585, CI 20)

12. Purim O*, Kundel Y*, Shapira R, Tichler T, Brenner B. (*Equal Contribution) Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancer: A Single Institution Experience. J Cancer Therapy. 2013 Apr;4(2):529-35. (No IF, CI )

1. Articles Published

13. Kundel Y, Nasser NJ, Purim O, Yerushalmi R, Fenig E, Pfeffer RM, Stemmer SM, Rizel S, Symon Z, Kaufman B, Sulkes A, Brenner B. Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin. PLoS One. 2013 Jul 10;8(7):e68327. (MULTIDISCIPLINARY SCIENCES JR 15/64, Q1, IF 2.806, CI 1)

14. Brenner RM, Kivity S, Kundel Y, Purim O, Peled N, Idelevich E, Lavrenkov K, Kovel S, Fenig E, Sulkes A, Brenner B. Ethnic variation in toxicity and outcome of adjuvant chemoradiation for gastric cancer in Israel. Anticancer Res. 2013 Nov;33(11):5151-7. (ONCOLOGY JR 161/217, Q3, IF 1.937, CI 0)

15. Dickman R, Kundel Y, Levy-Drummer R, Purim O, Wasserberg N, Fenig E, Sulkes A, Brenner B. Restaging locally advanced rectal cancer by different imaging modalities after preoperative chemoradiation: a comparative study. Radiat Oncol. 2013 Nov 29;8:278. (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING JR 38/127, Q2, IF 2.568, CI 4)

16. Berger Y, Zbar AP, Lebedyev A, Levi Y, Nevler A, Aderka D, Golan T, Purim O, Brenner B, Natur M, Gutman M. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin]. Harefuah. 2014 Jun;153(6):315-9, 368. (No IF, CI )

17. Vilkin A, Halpern M, Morgenstern S, Brazovski E, Gingold-Belfer R, Boltin D, Purim O, Kundel Y, Welinsky S, Brenner B, Niv Y, Levi Z. How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? Hum Pathol. 2014 Oct;45(10):2029-36. (PATHOLOGY JR 18/79, Q1, IF 3.014, CI 5)

18. Wasserberg N, Kundel Y, Purim O, Keidar A, Kashtan H, Sadot E, Fenig E, Brenner B. Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy. Radiat Oncol. 2014 Oct 22;9:233. (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING JR 38/127, Q2, IF 2.568, CI 1)

1. Articles Published

19. Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. Biomed Res Int. 2015;2015:681653. (BIOTECHNOLOGY & APPLIED MICROBIOLOGY JR 67/160, Q2, IF 2.476, CI 1)

20. Wasserberg N*, Purim O*, Bard V, Kundel Y, Gordon N, Groshar D, Goldberg N, Kashtan H, Sulkes A, Brenner B. (*Equal Contribution) Early postoperative 18F-FDG PET/CT in high-risk stage III colorectal cancer. Clin Nucl Med. 2015 Apr;40(4):e222-7. (RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING JR 12/127, Q1, IF 4.563, CI 3)

21. Levi M, Shalgi R, Brenner B, Perl G, Purim O, Amit L, Stemmer SM, Ben- Aharon I. The impact of oxaliplatin on the gonads: from bedside to the bench. Mol Hum Reprod. 2015 Dec;21(12):885-93. (OBSTETRICS & GYNECOLOGY JR 10/80, Q1, IF 3.585, CI 2)

22. Brenner B, Geva R, Rothney M, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, Gluzman A, Purim O, Shacham-Shmueli E, Shulman K, Mishaeli M, Man S, Soussan-Gutman L, Tezcan H, Chao C, Shani A, Liebermann N. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. Value Health. 2016 Jan;19(1):82-7. (HEALTH CARE SCIENCES & SERVICES JR 10/90, Q1, IF 4.235, CI 2)

23. Brenner B, Sarfaty M, Purim O, Kundel Y, Amit L, Abramovich A, Sadeh Gonik U, Idelevich E, Gordon N, Medalia G, Sulkes A. A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. PLoS One. 2016 Jul 8;11(7):e0157548. (MULTIDISCIPLINARY SCIENCES JR 15/64, Q1, IF 2.806, CI 1)

24. Perl G, Nordheimer S, Lando S, Benedict C, Brenner B, Perry S, Shmoisman G, Purim O, Amit L, Stemmer SM, Ben-Aharon I. Young patients and gastrointestinal (GI) tract malignancies - are we addressing the unmet needs? BMC Cancer. 2016 Aug 12;16:630. (ONCOLOGY JR 93/217, Q2, IF 3.288, CI 0) 1. Articles Published

25. Goldvaser H, Purim O, Kundel Y, Shepshelovich D, Shochat T, Shemesh-Bar L, Sulkes A, Brenner B. Colorectal cancer in young patients: is it a distinct clinical entity? Int J Clin Oncol. 2016 Aug;21(4):684-695. (ONCOLOGY JR 156/217, Q3, IF 2.064, CI 5)

26. Goldvaser H, Katz Shroitman N, Ben-Aharon I, Purim O, Kundel Y, Shepshelovich D, Shochat T, Sulkes A, Brenner B. Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. World J Gastroenterol. 2017 Feb 28;23(8):1387-1396. (GASTROENTEROLOGY & HEPATOLOGY JR 30/79, Q2, IF 3.365, CI 1)

27. Sarfaty M, Lankry E, Moore A, Kurman N, Purim O, Kundel Y, Ben-Aharon I, Perl G, Ulitsky O, Gordon N, Sulkes A, Menasherov N, Kashtan H, Brenner B. Esophageal Cancer in Israel has Unique Clinico-Pathological Features: A Retrospective Study. J Cancer. 2017 Jul 22;8(13):2417-2423. (ONCOLOGY JR 113/217, Q3, IF 2.916, CI 0)

28. Kundel Y, Nasser NJ, Rath-Wolfson L, Purim O, Yanichkin N, Brenner R, Zehavi T, Nardi Y, Fenig E, Sulkes A, Brenner B. Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer. Am J Clin Oncol. 2016 Oct 12. [Epub ahead of print] (ONCOLOGY JR 96/217, Q2, IF 3.259, CI )

29. Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, Peretz T, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience. Target Oncol. 2018 Jan 20. [Epub ahead of print] (ONCOLOGY JR 87/217, Q2, IF 3.438, CI )

30. Stemmer SM, Benjaminov O, Silverman MH, Sandler U, Purim O, Sender N, Meir C, Oren-Apoteker P, Ohana J, Devary Y. A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic solid tumors. Mol Clin Oncol. 2018 Jan;8(1):22-29. (No IF, CI )

1. Articles Published

31. Limon D, Gal O, Gordon N, Katz L, Perl G, Purim O, Amit L, Stemmer SM, Kundel Y, Ben-Aharon I, Brenner B, Siegal T, Yust-Katz S. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. J Neurooncol. 2018 Feb 10. [Epub ahead of print] (ONCOLOGY JR 111/217, Q3, IF 2.980, CI )

Case reports

1. Case Reports Published

1. Purim O, Sulkes A, Brenner B. Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. Anticancer Drugs. 2007 Jul;18(6):733-5. (PHARMACOLOGY & PHARMACY JR 135/257, Q3, IF 2.320, CI 0)

Reviews

1. Reviews Published

1. Brenner B, Purim O, Sulkes A. [Treatment approach to localized esophageal cancer--what have we learned so far?]. Harefuah. 2005 Jul;144(7):482-8, 526. (No IF, CI )

Letters

1. Rabinovics N, Hadar T, Mizrachi A, Bachar G, Purim O, Popovtzer A. Adjuvant treatment for head and neck cancer in solid organ transplant recipients. Oral Oncol. 2015 May;51(5):e23-5. (ONCOLOGY JR 53/217, Q1, IF 4.794, Cited 1)

14. Lecture and Presentations at National and International Meetings

1. Kundel Y, Idelevich E, Man S, Lavrencov K, Purim O, Kovel S, Pfeffer R, Salomon S, Sulkes J, Brenner B. Postoperative chemoradiation for resected gastric cancer: Is the MacDonald regimen tolerable? Ann Oncol. 2006;17(Suppl 6):95. Satellite Symposium on New Horizons for Gastric Cancer held in conjunction with the 8th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 29, 2006.

2. Purim O, Kundel Y, Figer A, Stemmer S, Sulkes A, Brenner B. Weekly infusional 5-fluorouracil and leucovorin and biweekly cisplatin, a convenient treatment option in advanced gastric cancer. Ann Oncol. 2006;17(Suppl 6):97-8. Satellite Symposium on New Horizons for Gastric Cancer held in conjunction with the 8th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 29, 2006.

3. Abramovich A, Idelevich E, Agbarya A, Figer A, Purim O, Sulkes J, Sulkes A, Brenner B. Gallbladder cancer in Israel: A retrospective analysis of 106 consecutive patients. Ann Oncol. 2007;18(Suppl 7):VII104. 9th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 28-Jul 01, 2007.

4. Purim O, Brenner B, Idelevich E, Gutman H, Feinmesser M, Ben Yosef R, Mahrshak G, Abramovich A, Sulkes A, Fenig E. Merkel cell carcinoma in Israel - A retrospective analysis of 76 consecutive patients. Ann Oncol. 2007;18(Suppl 9):188. ESMO Educational Conference Lugano (ECLU). Lugano, Switzerland, 2007.

5. Kundel Y, Brenner R, Abramovich A, Purim O, Peled N, Idelevich E, Nisenbaum B, Fenig E, Sulkes A, Brenner B. Prognostic factors for tumor histological response to preoperative chemoradiation in rectal cancer. J Clin Oncol. 2008 May 20;26(15 Suppl S):4094 (Meeting Abstract)

6. Brenner R, Shemesh-Bar L, Purim O, Kundel Y, Idelevich E, Abramovich A, Sulkes A, Brenner B. Colorectal cancer in young patients in Israel - A unique clinicopathological entity? Ann Oncol. 2008;19(Suppl 6):101. 10th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 25- 28, 2008.

14. Lecture and Presentations at National and International Meetings

7. Brenner R, Kundel Y, Idelevich E, Abramovich A, Purim O, Peled N, Nisenbaum B, Fenig E, Sulkes A, Brenner B. Restaging after preoperative chemoradiation for rectal cancer - Can it actually predict histological response to treatment? Ann Oncol. 2008;19(Suppl 5):141. Joint Annual Conference of the European Society of Medical Oncology/Japanese Society of Medical Oncology. Lugano, Switzerland, Jul 03-06, 2008.

8. Kundel Y, Brenner R, Purim O, Abramovich A, Peled N, Idelevich E, Nisenbaum B, Fenig E, Sulkes A, Brenner B. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option? Ann Oncol. 2008 Sep;19:143. 33rd European Society for Medical Oncology Congress. Stockholm, Sweden, Sep 12-16, 2008.

9. Brenner R, Kundel Y, Purim O, Peled N, Idelevich E, Lavrenkov K, Kovel S, Fenig E, Sulkes A, Brenner B. Comparison of toxicity, tolerability and outcome between Ashkenazi and Sephardic Jews in Israel receiving postoperative chemoradiation for locally advanced gastric cancer. Ann Oncol. 2008 Sep;19:175. 33rd European Society for Medical Oncology Congress. Stockholm, Sweden, Sep 12-16, 2008.

10. Kundel Y, Brenner R, Purim O, Abramovich A, Peled N, Idelevich E, Nisenbaum B, Fenig E, Sulkes A, Brenner B. Preoperative chemoradiation as initial management in locally advanced rectal cancer with synchronous metastases inadequate treatment option. Ann Oncol. 2009;20:58. 11th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 24- 27, 2009.

11. Kushnir M, Hoshen MB, Purim O, Meiri E, Cholakh H, Barabash N, Goren Y, Marshak G, Kundel Y, Morgenstern S, Halpern M, Niv Y, Chajut A, Brenner B. MicroRNAs as prognostic indicators in gastric cancer. Cancer Res. 2010 Apr;70(Suppl 8):3017 (Meeting Abstract)

12. Purim O, Hoshen M, Marshak G, Kundel Y, Morgenstern S, Halpern M, Aharonov R, Niv Y, Kushnir M, Brenner B. MicroRNAs as a potential factor in gastric cancer. J Clin Oncol. 2010 May 20;28(15 Suppl S):10635 (Meeting Abstract) 14. Lecture and Presentations at National and International Meetings

13. Ben-Aharon I, Kundel Y, Brenner R, Purim O, Sulkes A, Brenner B. Using the combination of docetaxel, cisplatin and 5-fluorouracil (DCF) in advanced gastric cancer: is it 'if' or simply 'how'? Ann Oncol. 2010;21(Suppl 6):91. 12th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 30- Jul 03, 2010.

14. Brenner R, Kundel Y, Purim O, Peled N, Ideldvich E, Nisenbaum B, Sulkes A, Fenig E, Brenner B. Clinical implication of microscopic residual disease after neoadjuvant chemoradiation for rectal cancer. Ann Oncol. 2010;21(Suppl 6):110. 12th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 30- Jul 03, 2010.

15. Purim O, Asman Y, Bard S, Kundel Y, Wasserberg N, Gordon N, Brenner B. The role of postoperative PET-CT in the evaluation of patients with high-risk stage III colorectal cancer (CRC). J Clin Oncol. 2011 Feb 1;29(4 Suppl S):566 (Meeting Abstract)

16. Purim O, Goldberg N, Kundel Y, Brenner R, Efremov N, Gordon N, Morgenstern S, Wasserberg N, Brenner B. Early prediction of pathological complete response (pCR) of rectal cancer after 1 week of preoperative radiochemotherapy (RCT) using positron emission computererized tomography (PET-CT) imaging. J Clin Oncol. 2011 Feb 1;29(4 Suppl S):572 (Meeting Abstract)

17. Purim O, Kundel Y, Idelevich E, Laverncov K, Karminsky, N Nisenbaum B, Fenig E, Sulkes A, Brenner B. Postoperative chemoradiation for resected gastric cancer-is the MacDonald regimen tolerable "in real life"? Ann Oncol. 2011 Jun;22(Suppl 5):v52. European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer. Barcelona, Spain, Jun 22-25, 2011.

18. Dickman R, Kundel Y, Brener R, Levy-Drummer RS, Purim O, Idelevich E, Wasserberg N, Fenig E, Sulkes A, Brener B. Restaging After Preoperative Chemoradiation for Locally Advanced Rectal Cancer: A Comparison Between Different Imaging Modalities. Gastrointest Endosc. 2012 Apr;75(4 Suppl S):322-3. Digestive Disease Week (DDW). San Diego, CA, May 19-22, 2012.

14. Lecture and Presentations at National and International Meetings

19. Purim O, Weismann-Brenner A, Kushnir M, Lithwick-Yanai G, Aharonov RT, Gibori H, Kundel Y, Morgenstern S, Halpern M, Niv Y, Brenner B. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. J Clin Oncol. 2012 May 20;30(15 Suppl S):e14067 (Meeting Abstract) 48th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, Jun 01-06, 2012.

20. Brenner B, Kundel Y, Purim O, Medalia G, Olshinka L, Kashtan H, Menasherov N, Fenig E, Sulkes A, Idelevich E. Preoperative chemoradiation and cetuximab for resectable, locally advanced esophageal cancer: Preliminary results of a prospective phase Ib/II trial. J Clin Oncol. 2012 May 20;30(15 Suppl S):e14571 (Meeting Abstract) 48th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, Jun 01-06, 2012.

21. Purim O, Kundel Y, Gonik US, Idelevich E, Medalia G, Gordon N, Sulkes A, Brenner B. Weekly docetaxel and cisplatin with capecitabine and bevacizumab (AVDCX) in patients with advanced esophagogastric cancer: Results of a phase Ib/II study. J Clin Oncol. 2013 May 20;31(15 Suppl S):e15078 (Meeting Abstract) 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, May 31-Jun 04, 2013.

22. Brenner B, Geva R, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, Gluzman A, Purim O, Shacham-Shmueli E, Shulman K, Soussan-Gutman L, Klang S, Merling S, Liebermann N. Association of the colon cancer recurrence score with treatments received in patients with stage II colon cancer: The experience. J Clin Oncol. 2013 May 20;31(15 Suppl S):e22111 (Meeting Abstract) 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, May 31-Jun 04, 2013.

23. Hubert A, Geva R, Segal A, Brenner B, Brenner RM, Pelles-Avraham S, Beny A, Sarld D, Karen-Rosenberg SP, Stemmer SM, Gabizon A, Purim O, Tahover E, Inbar MJ, Wolf I, Dvir A, Soussan-Gutman L, Ross JS, Stephens P, Miller VA. Next-generation sequencing (NGS) its metastatic colorectal cancer (CRC) patients (pts) in Israel. J Clin Oncol. 2014 May 20;32(15 Suppl S):e14548 (Meeting Abstract) 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, May 30-Jun 03, 2014.

14. Lecture and Presentations at National and International Meetings

24. Ben-Aharon I, Levi M, Brenner B, Purim O, Amit L, Stemmer SM, Shalgi R. The impact of oxaliplatin on the gonads: From bench to bedside. J Clin Oncol. 2015 Jan 20;33(3 Suppl S):584 (Meeting Abstract) Gastrointestinal Cancers Symposium. San Francisco, CA, Jan 15-17, 2015.

25. Stemmer SM, Benjaminov O, Silverman MH, Sandler U, Purim O, Sender N, Segal T, Meir C, Oren P, Ohana J, Devary Y. A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. J Clin Oncol. 2015 May 20;33(15 Suppl S):e14018 (Meeting Abstract) Annual Meeting of the American Society of Clinical Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer. Chicago, IL, May 29-Jun 02, 2015.

26. Goldvaser H, Purim O, Kundel Y, Ulitsky O, Shepshelovich D, Wasserberg N, Hananel N, Shemesh-Bar L, Shohat T, Sulkes A, Brenner B. Colorectal cancer in young patients: Is it a distinct clinical entity? J Clin Oncol. 2015 May 20;33(15 Suppl S):e14594 (Meeting Abstract) Annual Meeting of the American Society of Clinical Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer. Chicago, IL, May 29-Jun 02, 2015.

27. Sarfaty M, Purim O, Kundel Y, Ulitsky O, Menasherov N, Kashtan H, Sulkes A, Brenner B. Esophageal cancer in Israel: A unique clinicopathological entity? J Clin Oncol. 2015 May 20;33(15 Suppl S):e15050 (Meeting Abstract) Annual Meeting of the American Society of Clinical Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer. Chicago, IL, May 29-Jun 02, 2015.

28. Goldvaser H, Purim O, Kundel Y, Ulitsky O, Shepshelovich D, Wasserberg N, Hananel N, Shemesh-Bar L, Shochat T, Sulkes A, Brenner B. Colorectal cancer in young patients: is it a distinct clinical entity? Eur J Cancer. 2015 Sep;51(Suppl 3):S148. (Meeting Absract:1010) European Cancer Congress. Vienna, Austria, 2015.

29. Purim O, Beny A, Inbar MJ, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Sarid D, Semenisty V, Brenner RM, Peretz T, Idelevich E, Pelles S, Meirovitz A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A. Molecular profiling-selected treatment in metastatic gastric and oesophageal cancer: Real-life clinical experience. J Clin Oncol. 2017 May 20;35(Suppl 15):e15537 (Meeting Abstract) Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, Jun 02-06, 2017.

14. Lecture and Presentations at National and International Meetings

30. Brenner B, Purim O, Gordon N, Lago TG, Idelevich E, Kashtan H, Menasherov N, Fenig E. Association of the addition of cetuximab to preoperative chemoradiotherapy (CRT) for locally advanced esophageal squamous cell carcinoma (SqCC) with rate of long term survival: Mature results of a prospective phase Ib/II trial. J Clin Oncol. 2017 May 20;35(Suppl 15):4057 (Meeting Abstract) 42nd European Society for Medical Oncology Congress (ESMO). Madrid, Spain, Sep 08-12, 2017.

31. Moore A, Ben-Aharon I, Purim O, Pen G, Ulitsky O, Amit L, Kundel Y, Lewin R, Wasserberg N, Kashtan H, Brenner B. Early postoperative PET-CT in patients with pathological stage III colon cancer may change their outcome: Results from a large single-institution study. J Clin Oncol. 2017 May 20;35(Suppl 15):e15163 (Meeting Abstract) 42nd European Society for Medical Oncology Congress (ESMO). Madrid, Spain, Sep 08-12, 2017.

32. Moore A, Ben-Aharon I, Purim O, Perl G, Ulitsky O, Amit L, Kundel Y, Lewin R, Wasserberg N, Kashtan H, Brenner B. Early postoperative PET-CT in patients with pathological stage III colon cancer may change their outcome: Results from a large single institution study. Ann Oncol. 2017 Sep;28(Suppl 5):488P (Meeting Abstract) 42nd European Society for Medical Oncology Congress (ESMO). Madrid, Spain, Sep 08-12, 2017.

16. Present Academic Activities

Participation in Clinical Trials

Expected Subject Other participants date of completion Metronomic treatment to refractory Brenner B, Kundel Y, Amit L, Ben-Aharon 1. 2018 metastatic colorectal patients I, litzky O, Perl G, Loven D Phase 3 treatment of nentinib to 2. refractory metastatic colorectal Multi-International 2015 patients Phase 3 treatment of xilinox to 3. refractory metastatic colorectal Multi-International 2016 patients Phase 3 multi institutional trials including AVANT, ZEAL, HORIZON, PANDORA, 4. Multi-International 2010 ACCELOXX, S-TRAC,LOGIC and many more in areas of GI, breast, and genitourinary cancers Local phase 1/2-including neoadjuvant treatment with Brenner B, Kundel Y, Kashtan H, 5. cisplatin-5FU and cetuximab for 2017 Mansharov N, Idelevitch E, et al locally advanced esophageal carcinoma Basic science research in Brenner B, Abramovitz A, Weismann- 6. identifying mRNA's for various 2010 Brenner A, et al gastrointestinal tumors A phase 1 trial of a human thymus- Stemmer SM, Benjamino O, Silverman expressed apoptosis factor in 7. MH, Sandler U, Sender N, Segal T, Meir 2016 patients with advanced solid C, Oren P, Ohana J, Devary Y tumors A phase Ib/II study evaluating the combination of weekly docetaxel Brenner B, Sarfaty M, Kundel Y, Amit L, and cisplatin together with 8. Abramovich A, Gonik US, Idelevich E, 2014 capecitabine and bevacizumab in Gordon N, Medalia G, Sulkes A patients with advanced esophago- gastric cancer Association of the addition of cetuximab to preoperative chemoradiotherapy (CRT) for locally advanced esophageal Brenner B, Gordon N, Lao TG, Idelevich 9. 2014 squamous cell carcinoma (SqCC) E, Kashtan H, Menasherov N, Fenig E with rate of long term survival: mature results of a prospective phase Ib/II trial

18. Additional Information

Active Participation in Scientific Meetings

Date Country Name of Meeting

4th Annual Meeting of the Israeli Society for Clinical Oncology 2005 , Israel and Radiotherapy

2005 Budapest, Hungary ESEC Meeting

5th Annual Meeting of the Israeli Society for Clinical Oncology 2006 Eilat, Israel and Radiotherapy

2006 Barcelona, Spain 8th World Congress of GI Cancer

6th Annual Meeting of the Israeli Society for Clinical Oncology 2007 Eilat, Israel and Radiotherapy

2007 Lugano, Switzerland ECLU Congress

2008 Orlando, FL, USA American Society of Clinical Oncology (ASCO) GI Symposium

2009 Sintra, Portugal European Masterclass in Clinical Oncology

2010 Chicago, IL, USA ASCO Annual Meeting

2011 San Francisco, CA, USA ASCO GI Symposium

European Society for Medical Oncology (ESMO) Congress of 2011 Barcelona, Spain GI Cancer

2012 Chicago, IL, USA ASCO Annual Meeting

2012 Barcelona, Spain ESMO Congress of GI Cancer

2013 Barcelona, Spain European Neuroendocrine Tumor Society (ENETS) Congress

2013 Chicago, IL, USA ASCO Annual Meeting

2014 San Francisco, CA, USA ASCO GI Symposium

2014 Chicago, IL, USA ASCO Annual Meeting

Amsterdam, The 2014 GIST Master Class Netherlands

2015 Dublin, Ireland NET Master Class

2015 Chicago, IL, USA ASCO Annual Meeting

2016 Chicago, IL, USA ASCO Annual Meeting